Authors: FORD NF SONNICHSEN DS

Citation: Nf. Ford et Ds. Sonnichsen, CLINICALLY SIGNIFICANT CYTOCHROME-P-450 DRUG-INTERACTIONS - A COMMENT, Pharmacotherapy, 18(4), 1998, pp. 890-891

Authors: SONNICHSEN DS SUMMERILL RS RAYMOND RH WEINER RS ABRAMS JR BIRKHOFER MJ

Citation: Ds. Sonnichsen et al., PHARMACOKINETIC (PK) MODELING OF BMS-188667 (CTLA4IG), Clinical pharmacology and therapeutics, 61(2), 1997, pp. 104-104

Authors: SONNICHSEN DS LIU Q SCHUETZ EG SCHUETZ JD PAPPO A RELLING MV

Citation: Ds. Sonnichsen et al., VARIABILITY IN HUMAN CYTOCHROME-P450 PACLITAXEL METABOLISM, The Journal of pharmacology and experimental therapeutics, 275(2), 1995, pp. 566-575

Authors: SONNICHSEN DS RIBEIRO RC LUO XL MATHEW P RELLING MV

Citation: Ds. Sonnichsen et al., PHARMACOKINETICS AND PHARMACODYNAMICS OF 21-DAY CONTINUOUS ORAL ETOPOSIDE IN PEDIATRIC-PATIENTS WITH SOLID TUMORS, Clinical pharmacology and therapeutics, 58(1), 1995, pp. 99-107

Authors: SONNICHSEN DS HURWITZ CA PRATT CB SHUSTER JJ RELLING MV

Citation: Ds. Sonnichsen et al., SATURABLE PHARMACOKINETICS AND PACLITAXEL PHARMACODYNAMICS IN CHILDREN WITH SOLID TUMORS, Journal of clinical oncology, 12(3), 1994, pp. 532-538

Authors: SONNICHSEN DS RELLING MV

Citation: Ds. Sonnichsen et Mv. Relling, CLINICAL PHARMACOKINETICS OF PACLITAXEL, Clinical pharmacokinetics, 27(4), 1994, pp. 256-269